StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$80.00+1.06 (+1.34%)

Close on Nov 18, 2026Market cap $7.09BP/E –Yield –

CG Oncology net income

Net income is the profit left for shareholders after every expense, interest and tax.

CG Oncology's net income for the twelve months ending Sep 30, 2026 was -$237.46M. For fiscal 2025 it was -$161.00M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$161.00M–
FY2024Dec 31, 2024-$88.04M–
FY2023Dec 31, 2023-$48.61M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$56.89M–
Q2 FY2026Jun 30, 2026-$79.06M–
Q1 FY2026Mar 31, 2026-$60.20M–
Q4 FY2025Dec 31, 2025-$41.31M–
Q3 FY2025Sep 30, 2025-$43.81M–
Q2 FY2025Jun 30, 2025-$41.43M–
Q1 FY2025Mar 31, 2025-$34.45M–
Q4 FY2024Dec 31, 2024-$31.80M–
Q3 FY2024Sep 30, 2024-$20.41M–
Q2 FY2024Jun 30, 2024-$18.90M–
Q1 FY2024Mar 31, 2024-$16.93M–
Q4 FY2023Dec 31, 2023-$16.56M–
Q3 FY2023Sep 30, 2023-$11.77M–
Q2 FY2023Jun 30, 2023-$11.61M–
Q1 FY2023Mar 31, 2023-$8.67M–

More CG Oncology figures

See a number that looks wrong?